ANTI-SEMA3A ANTIBODIES AND USES THEREOF

The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ELLINGER, Philipp, FILARSKY, Katharina, MCALEESE ESER, Fionnuala Mary, WEBER, Ernst, FLAMME, Ingo, SEDAGHAT, Yalda, SCHMIDT, Antje, WUNDERLICH, Winfried, DRÖBNER, Karoline, SCHÖNFELD, Dorian, YOUNG, Kenneth
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ELLINGER, Philipp
FILARSKY, Katharina
MCALEESE ESER, Fionnuala Mary
WEBER, Ernst
FLAMME, Ingo
SEDAGHAT, Yalda
SCHMIDT, Antje
WUNDERLICH, Winfried
DRÖBNER, Karoline
SCHÖNFELD, Dorian
YOUNG, Kenneth
description The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4314047A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4314047A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4314047A13</originalsourceid><addsrcrecordid>eNrjZFB39Avx1A129XU0dlQAsZ38XTxdg4FMF4XQYCAjxMM1yNXfjYeBNS0xpziVF0pzMyi4uYY4e-imFuTHpxYXJCan5qWWxLsGmBgbmhiYmDsaGhOhBACABCMZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><source>esp@cenet</source><creator>ELLINGER, Philipp ; FILARSKY, Katharina ; MCALEESE ESER, Fionnuala Mary ; WEBER, Ernst ; FLAMME, Ingo ; SEDAGHAT, Yalda ; SCHMIDT, Antje ; WUNDERLICH, Winfried ; DRÖBNER, Karoline ; SCHÖNFELD, Dorian ; YOUNG, Kenneth</creator><creatorcontrib>ELLINGER, Philipp ; FILARSKY, Katharina ; MCALEESE ESER, Fionnuala Mary ; WEBER, Ernst ; FLAMME, Ingo ; SEDAGHAT, Yalda ; SCHMIDT, Antje ; WUNDERLICH, Winfried ; DRÖBNER, Karoline ; SCHÖNFELD, Dorian ; YOUNG, Kenneth</creatorcontrib><description>The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240207&amp;DB=EPODOC&amp;CC=EP&amp;NR=4314047A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240207&amp;DB=EPODOC&amp;CC=EP&amp;NR=4314047A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ELLINGER, Philipp</creatorcontrib><creatorcontrib>FILARSKY, Katharina</creatorcontrib><creatorcontrib>MCALEESE ESER, Fionnuala Mary</creatorcontrib><creatorcontrib>WEBER, Ernst</creatorcontrib><creatorcontrib>FLAMME, Ingo</creatorcontrib><creatorcontrib>SEDAGHAT, Yalda</creatorcontrib><creatorcontrib>SCHMIDT, Antje</creatorcontrib><creatorcontrib>WUNDERLICH, Winfried</creatorcontrib><creatorcontrib>DRÖBNER, Karoline</creatorcontrib><creatorcontrib>SCHÖNFELD, Dorian</creatorcontrib><creatorcontrib>YOUNG, Kenneth</creatorcontrib><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><description>The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB39Avx1A129XU0dlQAsZ38XTxdg4FMF4XQYCAjxMM1yNXfjYeBNS0xpziVF0pzMyi4uYY4e-imFuTHpxYXJCan5qWWxLsGmBgbmhiYmDsaGhOhBACABCMZ</recordid><startdate>20240207</startdate><enddate>20240207</enddate><creator>ELLINGER, Philipp</creator><creator>FILARSKY, Katharina</creator><creator>MCALEESE ESER, Fionnuala Mary</creator><creator>WEBER, Ernst</creator><creator>FLAMME, Ingo</creator><creator>SEDAGHAT, Yalda</creator><creator>SCHMIDT, Antje</creator><creator>WUNDERLICH, Winfried</creator><creator>DRÖBNER, Karoline</creator><creator>SCHÖNFELD, Dorian</creator><creator>YOUNG, Kenneth</creator><scope>EVB</scope></search><sort><creationdate>20240207</creationdate><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><author>ELLINGER, Philipp ; FILARSKY, Katharina ; MCALEESE ESER, Fionnuala Mary ; WEBER, Ernst ; FLAMME, Ingo ; SEDAGHAT, Yalda ; SCHMIDT, Antje ; WUNDERLICH, Winfried ; DRÖBNER, Karoline ; SCHÖNFELD, Dorian ; YOUNG, Kenneth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4314047A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ELLINGER, Philipp</creatorcontrib><creatorcontrib>FILARSKY, Katharina</creatorcontrib><creatorcontrib>MCALEESE ESER, Fionnuala Mary</creatorcontrib><creatorcontrib>WEBER, Ernst</creatorcontrib><creatorcontrib>FLAMME, Ingo</creatorcontrib><creatorcontrib>SEDAGHAT, Yalda</creatorcontrib><creatorcontrib>SCHMIDT, Antje</creatorcontrib><creatorcontrib>WUNDERLICH, Winfried</creatorcontrib><creatorcontrib>DRÖBNER, Karoline</creatorcontrib><creatorcontrib>SCHÖNFELD, Dorian</creatorcontrib><creatorcontrib>YOUNG, Kenneth</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ELLINGER, Philipp</au><au>FILARSKY, Katharina</au><au>MCALEESE ESER, Fionnuala Mary</au><au>WEBER, Ernst</au><au>FLAMME, Ingo</au><au>SEDAGHAT, Yalda</au><au>SCHMIDT, Antje</au><au>WUNDERLICH, Winfried</au><au>DRÖBNER, Karoline</au><au>SCHÖNFELD, Dorian</au><au>YOUNG, Kenneth</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-SEMA3A ANTIBODIES AND USES THEREOF</title><date>2024-02-07</date><risdate>2024</risdate><abstract>The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP4314047A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ANTI-SEMA3A ANTIBODIES AND USES THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T05%3A49%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ELLINGER,%20Philipp&rft.date=2024-02-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4314047A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true